Problems associated with fluid biomarkers for Parkinsons disease

Biomarkers in Medicine

Volumn 4, Issue 5, 2010, Pages 671-681

  Nyhlén, Jakob ^a   Constantinescu, Radu ^a   Zetterberg, Henrik ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

synuclein; A 1 42; biomarkers; cerebrospinal fluid; DJ 1; neurofilament; Parkinson's disease; plasma; Tau; urine

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; ALPHA SYNUCLEIN; AMINO ACID; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; CYTOKINE; DJ 1 PROTEIN; HOMOVANILLIC ACID; ISOPROSTANE DERIVATIVE; LIPID; NEUROFILAMENT PROTEIN; OREXIN; OSTEOPONTIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; TAU PROTEIN; URATE;

BLOOD LEVEL; BODY FLUID; CEREBROSPINAL FLUID; DEGENERATIVE DISEASE; DISEASE MARKER; GENE EXPRESSION; HUMAN; LIPID OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN FUNCTION; REVIEW; RISK FACTOR; URINALYSIS;

ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; INTERLEUKINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; METHOXYHYDROXYPHENYLGLYCOL; ONCOGENE PROTEINS; PARKINSON DISEASE; PEPTIDE FRAGMENTS; TAU PROTEINS; URIC ACID;

EID: 77958065565     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.84     Document Type: Review

References (121)

1. Samii A, Nutt JG, Ransom BR: Parkinson's disease. Lancet 363(9423), 1783-1793 (2004).
2. Jellinger KA: Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol. Chem. Neuropathol. 14(3), 153-197 (1991).
3. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55(3), 181-184 (1992).
4. Booij J, Bergmans P, Winogrodzka A, Speelman JD, Wolters EC: Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. Synapse 39(2), 101-108 (2001).
5. Guttman M, Burkholder J, Kish SJ et al.: [11C] RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology 48(6), 1578-1583 (1997).
6. Schapira AH: Disease modification in Parkinson's disease. Lancet Neurol. 3(6), 362-368 (2004).
7. Constantinescu R, Zetterberg H, Holmberg B, Rosengren L: Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders. Parkinsonism Relat. Disord. 15(3), 205-212 (2009).
8. Molina JA, Jimenez-Jimenez FJ, Gomez P et al.: Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease. J. Neurol Sci 150(2), 123-127 (1997).
9. Bernheimer H, Birkmayer W, Hornykiewicz O: [Homovanillic acid in the cerebrospinal fluid: studies in Parkinson's syndrome and other diseases of the CNS]. Wien. Klin. Wochenschr. 78(23), 417-419 (1966).
10. Chase TN, Ng LK: Central monoamine metabolism in Parkinson's disease. Arch. Neurol. 27(6), 486-491 (1972).
11. Rinne UK, Sonninen V: Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's disease. Neurology 22(1), 62-67 (1972).
12. Chase T: Neurochemical alterations in Parkinson's disease. Neurobiol. Cerebrospinal Fluid 1, 207-218 (1980).
13. Chia LG, Cheng LJ, Chuo LJ, Cheng FC, Cu JS: Studies of dementia, depression, electrophysiology and cerebrospinal fluid monoamine metabolites in patients with Parkinson's disease. J. Neurol. Sci. 133(1-2), 73-78 (1995).
14. Wilk S, Mones R: Cerebrospinal fluid levels of 3-methoxy-4- hydroxyphenylethylene glycol in parkinsonism before and after treatment with l-dopa. J. Neurochem. 18(9), 1771-1773 (1971).
15. Chase TN, Gordon EK, Ng LK: Norepinephrine metabolism in the central nervous system of man: studies using 3-methoxy-4-hydroxyphenylethylene glycol levels in cerebrospinal fluid. J. Neurochem. 21(3), 581-587 (1973).
16. Davidson DL, Yates CM, Mawdsley C, Pullar IA, Wilson H: CSF studies on the relationship between dopamine and 5-hydroxytryptamine in parkinsonism and other movement disorders. J. Neurol. Neurosurg. Psychiatry 40(12), 1136-1141 (1977).
17. Abdo WF, De Jong D, Hendriks JC et al.: Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease. Mov. Disord. 19(5), 571-579 (2004).
18. Abdo WF, Bloem BR, Van Geel WJ, Esselink RA, Verbeek MM: CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol. Aging 28(5), 742-747 (2007).
19. Gumpert J, Sharpe D, Curzon G: Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa. J. Neurol. Sci. 19(1), 1-12 (1973).
20. Van Woert MH, Bowers MB Jr: The effect of l-dopa on monoamine metabolites in Parkinson's disease. Experientia 26(2), 161-163 (1970).
21. Chartier-Harlin MC, Kachergus J, Roumier C et al.: a-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364(9440), 1167-1169 (2004).
22. Ibanez P, Bonnet AM, Debarges B et al.: Causal relation between a-synuclein gene duplication and familial Parkinson's disease. Lancet 364(9440), 1169-1171 (2004).
23. Singleton AB, Farrer M, Johnson J et al.: a-synuclein locus triplication causes Parkinson's disease. Science 302(5646), 841 (2003).
24. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M: a-synuclein in Lewy bodies. Nature 388(6645), 839-840 (1997).
25. Uversky VN: Intrinsic disorder in proteins associated with neurodegenerative diseases. Front. Biosci. 14, 5188-5238 (2009).
26. Maraganore DM, de Andrade M, Elbaz A et al.: Collaborative analysis of a-synuclein gene promoter variability and Parkinson disease. JAMA 296(6), 661-670 (2006).
27. Chiba-Falek O, Nussbaum RL: Effect of allelic variation at the NACP-Rep1 repeat upstream of the a-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum. Mol. Genet. 10(26), 3101-3109 (2001).
28. El-Agnaf OM, Salem SA, Paleologou KE et al.: a-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 17(13), 1945-1947 (2003).
29. Tokuda T, Salem SA, Allsop D et al.: Decreased a-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349(1), 162-166 (2006).
30. Mollenhauer B, Cullen V, Kahn I et al.: Direct quantification of CSF a-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 213(2), 315-325 (2008).
31. Hong Z, Shi M, Chung KA et al.: DJ-1 and a-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133(Pt 3), 713-726 (2010).
32. Ohrfelt A, Grognet P, Andreasen N et al.: Cerebrospinal fluid a-synuclein in neurodegenerative disorders - a marker of synapse loss? Neurosci. Lett. 450(3), 332-335 (2008).
33. Borghi R, Marchese R, Negro A et al.: Full length a-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci. Lett. 287(1), 65-67 (2000).
34. Jakowec MW, Petzinger GM, Sastry S, Donaldson DM, Mccormack A, Langston JW: The native form of a-synuclein is not found in the cerebrospinal fluid of patients with Parkinson's disease or normal controls. Neurosci. Lett. 253(1), 13-16 (1998).
35. Kasuga K, Tokutake T, Ishikawa A et al.: Differential levels of a-synuclein, b-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 81(6), 608-610 (2010).
36. Noguchi-Shinohara M, Tokuda T, Yoshita M et al.: CSF a-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res. 1251, 1-6 (2009).
37. Mollenhauer B, Schlossmacher MG: CSF synuclein: Adding to the biomarker footprint of dementia with Lewy bodies. J. Neurol. Neurosurg. Psychiatry 81(6), 590-591 (2010).
38. El-Agnaf OM, Walsh DM, Allsop D: Soluble oligomers for the diagnosis of neurodegenerative diseases. Lancet Neurol. 2(8), 461-462 (2003).
39. Paleologou KE, Kragh CL, Mann DM et al.: Detection of elevated levels of soluble a-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 132(Pt 4), 1093-1101 (2009).
40. Fukumoto H, Tokuda T, Kasai T et al.: High-molecular-weight b-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J. 24(8), 2716-2726 (2010).
41. Michell AW, Luheshi LM, Barker RA: Skin and platelet a-synuclein as peripheral biomarkers of Parkinson's disease. Neurosci. Lett. 381(3), 294-298 (2005).
42. Brighina L, Prigione A, Begni B et al.: Lymphomonocyte a-synuclein levels in aging and in Parkinson disease. Neurobiol. Aging 31(5), 884-885
43. El-Agnaf OM, Salem SA, Paleologou KE et al.: Detection of oligomeric forms of a-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 20(3), 419-425 (2006).
44. Giasson BI, Duda JE, Murray IV et al.: Oxidative damage linked to neurodegeneration by selective a-synuclein nitration in synucleinopathy lesions. Science 290(5493), 985-989 (2000).
45. Cavallarin N, Vicario M, Negro A: The role of phosphorylation in synucleinopathies: focus on Parkinson's disease. CNS Neurol. Disord. Drug Targets 9(4), 471-481 (2010).
46. Liu CW, Giasson BI, Lewis KA, Lee VM, Demartino GN, Thomas PJ: A precipitating role for truncated a-synuclein and the proteasome in a-synuclein aggregation: implications for pathogenesis of Parkinson disease. J. Biol. Chem. 280(24), 22670-22678 (2005).
47. Lev N, Ickowicz D, Melamed E, Offen D: Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection. Neurotoxicology 29(3), 397-405 (2008).
48. Kahle PJ, Waak J, Gasser T: DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. Free Radic. Biol. Med. 47(10), 1354-1361 (2009).
49. Klein C, Schneider SA, Lang AE: Hereditary parkinsonism: Parkinson disease look-alikes - an algorithm for clinicians to "Park" Genes and beyond. Mov. Disord. 24(14), 2042-2058 (2009).
50. Hattori N, Kobayashi H, Sasaki-Hatano Y, Sato K, Mizuno Y: Familial Parkinson's disease: a hint to elucidate the mechanisms of nigral degeneration. J. Neurol. 250(Suppl. 3), III2-III10 (2003).
51. Hirotani M, Maita C, Niino M et al.: Correlation between DJ-1 levels in the cerebrospinal fluid and the progression of disabilities in multiple sclerosis patients. Mult. Scler. 14(8), 1056-1060 (2008).
52. Maita C, Tsuji S, Yabe I et al.: Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci. Lett. 431(1), 86-89 (2008).
53. Waragai M, Wei J, Fujita M et al.: Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem. Biophys. Res. Commun. 345(3), 967-972 (2006).
54. Waragai M, Nakai M, Wei J et al.: Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease. Neurosci. Lett. 425(1), 18-22 (2007).
55. Norgren N, Rosengren L, Stigbrand T: Elevated neurofilament levels in neurological diseases. Brain Res. 987(1), 25-31 (2003).
56. Zetterberg H, Hietala MA, Jonsson M et al.: Neurochemical aftermath of amateur boxing. Arch. Neurol. 63(9), 1277-1280 (2006).
57. Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM: Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur. J. Neurol. 14(12), 1329-1333 (2007).
58. Holmberg B, Rosengren L, Karlsson JE, Johnels B: Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease. Mov. Disord. 13(1), 70-77 (1998).
59. Holmberg B, Johnels B, Ingvarsson P, Eriksson B, Rosengren L: CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of parkinsonian syndromes. Parkinsonism Relat. Disord. 8(1), 23-31 (2001).
60. Abdo WF, Van De Warrenburg BP, Kremer HP, Bloem BR, Verbeek MM: CSF biomarker profiles do not differentiate between the cerebellar and parkinsonian phenotypes of multiple system atrophy. Parkinsonism Relat. Disord. 13(8), 480-482 (2007).
61. Abdo WF, Van De Warrenburg BP, Munneke M et al.: CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia. Neurology 67(3), 474-479 (2006).
62. Constantinescu R, Rosengren L, Johnels B, Zetterberg H, Holmberg B: Consecutive analyses of cerebrospinal fluid axonal and glial markers in parkinson's disease and atypical parkinsonian disorders. Parkinsonism Relat. Disord. 16(2), 142-145 (2010).
63. Brettschneider J, Petzold A, Sussmuth SD et al.: Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of parkinsonian syndromes. Mov. Disord. 21(12), 2224-2227 (2006).
64. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ: Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp. Gerontol. 45(1), 30-40 (2010).
65. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E: Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol. Chem. Neuropathol. 26(3), 231-245 (1995).
66. Kahle PJ, Jakowec M, Teipel SJ et al.: Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. Neurology 54(7), 1498-1504 (2000).
67. Lins H, Wichart I, Bancher C, Wallesch CW, Jellinger KA, Rosler N: Immunoreactivities of amyloid-b peptide((1-42)) and total tau protein in lumbar cerebrospinal fluid of patients with normal pressure hydrocephalus. J. Neural. Transm. 111(3), 273-280 (2004).
68. Paraskevas GP, Kapaki E, Liappas I et al.: The diagnostic value of cerebrospinal fluid tau protein in dementing and nondementing neuropsychiatric disorders. J. Geriatr. Psychiatry Neurol. 18(3), 163-173 (2005).
69. Andreasson U, Portelius E, Andersson ME, Blennow K, Zetterberg H: Aspects of b-amyloid as a biomarker for Alzheimer's disease. Biomarkers Med. 1(1), 59-78 (2007).
70. Sjogren M, Minthon L, Davidsson P et al.: CSF levels of tau, b-amyloid1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J. Neural. Transm. 107(5), 563-579 (2000).
71. Sjogren M, Davidsson P, Tullberg M et al.: Both total and phosphorylated tau are increased in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 70(5), 624-630 (2001).
72. Holmberg B, Johnels B, Blennow K, Rosengren L: Cerebrospinal fluid Ab42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov. Disord. 18(2), 186-190 (2003).
73. Mollenhauer B, Bibl M, Esselmann H et al.: Tauopathies and synucleinopathies: do cerebrospinal fluid b-amyloid peptides reflect disease-specific pathogenesis? J. Neural. Transm. 114(7), 919-927 (2007).
74. Bibl M, Mollenhauer B, Esselmann H et al.: CSF amyloid-b-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 129(Pt 5), 1177-1187 (2006).
75. Mollenhauer B, Trenkwalder C, Von Ahsen N et al.: b-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement. Geriatr. Cogn. Disord. 22(3), 200-208 (2006).
76. Alves G, Bronnick K, Aarsland D et al.: CSF amyloid-b and tau proteins, and cognitive performance, in early and untreated parkinson's disease: The Norwegian Parkwest study. J. Neurol. Neurosurg. Psychiatry (2010) (Epub ahead of print).
77. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ 2nd: Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann. Neurol. 44(3), 410-413 (1998).
78. Montine TJ, Beal MF, Cudkowicz ME et al.: Increased CSF F2-isoprostane concentration in probable AD. Neurology 52(3), 562-565 (1999).
79. Fessel JP, Hulette C, Powell S, Roberts LJ, 2nd, Zhang J: Isofurans, but not F2- isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. J. Neurochem. 85(3), 645-650 (2003).
80. Connolly J, Siderowf A, Clark CM, Mu D, Pratico D: F2 isoprostane levels in plasma and urine do not support increased lipid peroxidation in cognitively impaired Parkinson disease patients. Cogn. Behav. Neurol. 21(2), 83-86 (2008).
81. Lee CY, Seet RC, Huang SH, Long LH, Halliwell B: Different patterns of oxidized lipid products in plasma and urine of dengue fever, stroke, and Parkinson's disease patients: cautions in the use of biomarkers of oxidative stress. Antioxid. Redox Signal 11(3), 407-420 (2009).
82. Brodacki B, Staszewski J, Toczylowska B et al.: Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNF-a, and INF-g concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci. Lett. 441(2), 158-162 (2008).
83. Dufek M, Hamanova M, Lokaj J et al.: Serum inflammatory biomarkers in Parkinson's disease. Parkinsonism Relat. Disord. 15(4), 318-320 (2009).
84. Scalzo P, Kummer A, Cardoso F, Teixeira AL: Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance. Neurosci. Lett. 468(1), 56-58 (2010).
85. Bessler H, Djaldetti R, Salman H, Bergman M, Djaldetti M: IL-1 b, IL-2, IL-6 and TNF-a production by peripheral blood mononuclear cells from patients with Parkinson's disease. Biomed. Pharmacother. 53(3), 141-145 (1999).
86. Muller T, Blum-Degen D, Przuntek H, Kuhn W: Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta. Neurol. Scand. 98(2), 142-144 (1998).
87. Reale M, Iarlori C, Thomas A et al.: Peripheral cytokines profile in Parkinson's disease. Brain Behav. Immun. 23(1), 55-63 (2009).
88. Sawada M, Imamura K, Nagatsu T: Role of cytokines in inflammatory process in Parkinson's disease. J. Neural. Transm. Suppl. (70), 373-381 (2006).
89. Simonsen AH, Mcguire J, Hansson O et al.: Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch. Neurol. 64(3), 366-370 (2007).
90. Mattsson N, Ruetschi U, Pijnenburg YA et al.: Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia. Mol. Med. Reports 1(5), 757-761 (2008).
91. Maetzler W, Berg D, Schalamberidze N et al.: Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol. Dis. 25(3), 473-482 (2007).
92. Fesus L, Szondy Z: Transglutaminase 2 in the balance of cell death and survival. FEBS Lett. 579(15), 3297-3302 (2005).
93. Segers-Nolten IM, Wilhelmus MM, Veldhuis G, Van Rooijen BD, Drukarch B, Subramaniam V: Tissue transglutaminase modulates a-synuclein oligomerization. Protein Sci. 17(8), 1395-1402 (2008).
94. Vermes I, Steur EN, Jirikowski GF, Haanen C: Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson's disease indicating apoptosis. Mov. Disord. 19(10), 1252-1254 (2004).
95. Menza M, Dobkin RD, Marin H, Bienfait K: Sleep disturbances in Parkinson's disease. Mov. Disord. 25(Suppl. 1), S117-S122 (2010).
96. Yasui K, Inoue Y, Kanbayashi T, Nomura T, Kusumi M, Nakashima K: CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J. Neurol. Sci. 250(1-2), 120-123 (2006).
97. Mignot E, Lammers GJ, Ripley B et al.: The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol. 59(10), 1553-1562 (2002).
98. Baumann C, Ferini-Strambi L, Waldvogel D, Werth E, Bassetti CL: Parkinsonism with excessive daytime sleepiness - a narcolepsy-like disorder? J. Neurol. 252(2), 139-145 (2005).
99. Schlesinger I, Schlesinger N: Uric acid in Parkinson's disease. Mov. Disord. 23(12), 1653-1657 (2008).
100. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A: Plasma urate and risk of Parkinson's disease. Am. J. Epidemiol. 166(5), 561-567 (2007). (Pubitemid 47283643)
101. Ascherio A, Lewitt PA, Xu K et al.: Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch. Neurol. 66(12), 1460-1468 (2009).
102. Annanmaki T, Pessala-Driver A, Hokkanen L, Murros K: Uric acid associates with cognition in Parkinson's disease. Parkinsonism Relat. Disord. 14(7), 576-578 (2008).
103. Basso M, Giraudo S, Corpillo D, Bergamasco B, Lopiano L, Fasano M: Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 4(12), 3943-3952 (2004).
104. Jin J, Hulette C, Wang Y et al.: Proteomic identification of a stress protein, mortalin/ mthsp70/GRP75: relevance to Parkinson disease. Mol. Cell Proteomics 5(7), 1193-1204 (2006).
105. Werner CJ, Heyny-Von Haussen R, Mall G, Wolf S: Proteome analysis of human substantia nigra in Parkinson's disease. Proteome Sci. 6, 8 (2008).
106. Abdi F, Quinn JF, Jankovic J et al.: Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis. 9(3), 293-348 (2006).
107. Constantinescu R, Andreasson U, Li S et al.: Proteomic profiling of cerebrospinal fluid in parkinsonian disorders. Parkinsonism Relat. Disord. 16(8), 545-549 (2010).
108. Zetterberg H, Ruetschi U, Portelius E et al.: Clinical proteomics in neurodegenerative disorders. Acta. Neurol. Scand. 118(1), 1-11 (2008).
109. Kaddurah-Daouk R, Krishnan KR: Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 34(1), 173-186 (2009).
110. Johansen KK, Wang L, Aasly JO et al.: Metabolomic profiling in LRRK2-related Parkinson's disease. PLoS ONE 4(10), e7551 (2009).
111. Bogdanov M, Matson WR, Wang L et al.: Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 131(Pt 2), 389-396 (2008).
112. Quinones MP, Kaddurah-Daouk R: Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol. Dis. 35(2), 165-176 (2009).
113. Scherzer CR, Eklund AC, Morse LJ et al.: Molecular markers of early Parkinson's disease based on gene expression in blood. Proc. Natl Acad. Sci. USA 104(3), 955-960 (2007).
114. Chen JJ: Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment. Am. J. Manag. Care 16(Suppl.), S87-S93 (2010).
115. Hauser RA: Early pharmacologic treatment in Parkinson's disease. Am. J. Manag. Care 16(Suppl.), S100-S107 (2010).
116. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, Laferla FM: Synergistic interactions between Ab, tau, and a-synuclein: acceleration of neuropathology and cognitive decline. J. Neurosci. 30(21), 7281-7289 (2010).
117. Halliday GM, McCann H: The progression of pathology in Parkinson's disease. Ann. NY Acad. Sci. 1184, 188-195 (2010).
118. Mattsson N, Zetterberg H: Alzheimer's disease and CSF biomarkers: key challenges for broad clinical applications. Biomark. Med. 3(6), 735-737 (2009).
119. Teunissen CE, Petzold A, Bennett JL et al.: A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73(22), 1914-1922 (2009).
120. Mattsson N, Blennow K, Zetterberg H: Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Clin. Chem. Lab. Med. 48(5), 603-607 (2010).
121. Portelius E, Andreasson U, Ringman JM et al.: Distinct cerebrospinal fluid amyloid-b peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease. Mol. Neurodegener. 5, 2 (2010).